Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
In vitro effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 5′-amino-5-iodo-2′,5′-dideoxyuridine and 2-deoxy-d-glucose on latent ganglionic herpes simplex virus infection — Deborah Pavan‐Langston (1984) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
In vitro effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 5′-amino-5-iodo-2′,5′-dideoxyuridine and 2-deoxy-d-glucose on latent ganglionic herpes simplex virus infection
Shared by
De Clercq Erik
KU Leuven
In vitro effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 5′-amino-5-iodo-2′,5′-dideoxyuridine and 2-deoxy-d-glucose on latent ganglionic herpes simplex virus infection
Article
1984
en
Authors
DP
Deborah Pavan‐Langston
NP
No-Hee Park
De Clercq Erik
KU Leuven
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
1985
Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2′-deoxyuridine cream
Donna Freeman
,
Stephen L. Sacks
,
De Clercq Erik
,
Spotswood L. Spruance
Article
1987
Comparative metabolism of E-5-(2-bromovinyl)-2'-deoxyuridine and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in herpes simplex virus-infected cells.
Nana K. Ayisi
,
Richard A. Wall
,
R. James Wanklin
,
H. Machida
,
De Clercq Erik
,
Stephen L. Sacks
Article
1984
Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on synthesis of herpes simplex virus type 1-specific polypeptides
Scott A. Siegel
,
Michaël Otto
,
De Clercq Erik
,
William H. Prusoff
Article
1982
Effect of acyclovir, bromovinyldeoxyuridine, vidarabine, and l-lysine on latent ganglionic herpes simplex virus in vitro
No-Hee Park
,
Deborah Pavan‐Langston
,
De Clercq Erik
Article
1987
The effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1
Glenn J. Bubley
,
Jan Balzarini
,
Clyde S. Crumpacker
,
De Clercq Erik
,
Lowell E. Schnipper
Discussion(0)
No comments yet. Be the first to comment.